Abstract Number: 1752 • ACR Convergence 2021
Efficacy of Voclosporin in Recent Onset Lupus Nephritis
Background/Purpose: Voclosporin is a novel calcineurin inhibitor recently approved for the treatment of adults with active lupus nephritis (LN) in combination with background immunosuppressive therapy.…Abstract Number: 1823 • ACR Convergence 2021
Efficacy of Upadacitinib in Patients with Active Psoriatic Arthritis and a Low or High Swollen Joint Count: A Subgroup Analysis of 2 Phase 3 Studies
Background/Purpose: Although most patients with psoriatic arthritis (PsA) enrolled in clinical trials have polyarticular arthritis, patients in clinical practice may present with oligoarthritis. Data on…Abstract Number: 0497 • ACR Convergence 2021
Efficacy in Patient Subgroups in the INCREASE Trial, a Phase III Trial to Evaluate Inhaled Treprostinil in Patients with Pulmonary Hypertension Due to Parenchymal Lung Disease
Background/Purpose: INCREASE was a 16-week trial evaluating the safety and efficacy of inhaled treprostinil (iTRE) in patients with pulmonary hypertension associated with interstitial lung disease…Abstract Number: 1240 • ACR Convergence 2021
Biomarker Driven Dissection of Inflammation Modulatory Effects of Upadacitinib versus Abatacept in Patients with Active Rheumatoid Arthritis Refractory to Biologic DMARDs
Background/Purpose: In patients with active rheumatoid arthritis (RA) refractory to biologic DMARDs (bDMARD-IR), a phase 3, double-blind and active-controlled study (SELECT-CHOICE) demonstrated that upadacitinib (UPA)…Abstract Number: 1396 • ACR Convergence 2021
Baricitinib in Relapsing Giant Cell Arteritis: A Prospective Open-Label Single-Institution Study
Background/Purpose: Pre-clinical giant cell arteritis (GCA) mouse models have demonstrated effective suppression of arterial wall lesional T-cells through inhibition of Janus kinase 3 (JAK3) and…Abstract Number: 1697 • ACR Convergence 2021
Clinical Outcomes up to Week 48 of Filgotinib Treatment in an Ongoing Long-term Extension Trial of RA Patients with Inadequate Response to MTX Initially Treated with Filgotinib or Adalimumab During the Phase 3 Parent Trial
Background/Purpose: The preferential Janus kinase (JAK)-1 inhibitor filgotinib (FIL) is approved for treatment of moderately to severely active RA in Europe and Japan. We assessed…Abstract Number: 1755 • ACR Convergence 2021
Increasing Participation of Underrepresented Groups in Lupus Clinical Trials: Insights from Qualitative Interviews with Patients and Physicians
Background/Purpose: Systemic lupus erythematosus disproportionately affects Black/African American (AA) and Latino/a populations.1 Challenges to engage and include these populations in clinical trials (CTs) can be…Abstract Number: 1834 • ACR Convergence 2021
To What Extent Do Clinical Features of PsA Predict Achievement of Minimal Disease Activity at Week 24: A Post Hoc Analysis of the Phase III Clinical Trial Program of Guselkumab in a Bio-naïve Patient Population
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19-subunit, has demonstrated efficacy across joint and skin endpoints at Week 24 (W24) in the Phase…Abstract Number: 0112 • ACR Convergence 2021
A Randomized Trial Showing No Differences in Patient Satisfaction with Telemedicine Delivered by Phone or Video During COVID-19 in Rheumatology and Other Medical Specialty Clinics
Background/Purpose: The COVID-19 pandemic has led to a significant shift to home-based telemedicine including video and phone-only visits in many medical specialties. However, patients may…Abstract Number: 0603 • ACR Convergence 2021
Barriers and Potential Solutions in the Recruitment and Retention of Older Patients in Clinical Trials – Lessons Learned from Six Large Multi-center Randomized Controlled Trials
Background/Purpose: Older people remain underrepresented in clinical trials, and evidence generated in younger populations cannot always be generalized to older patients.We aimed to identify key…Abstract Number: 1241 • ACR Convergence 2021
Comparison of the Effects of Upadacitinib Monotherapy with MTX on Protein Biomarkers in MTX-Naïve and MTX-Inadequate Responders in Patients with Active Rheumatoid Arthritis: Results from the SELECT-EARLY and SELECT‑MONOTHERAPY Phase 3 Studies
Background/Purpose: In MTX-naïve patients (SELECT-EARLY/M13-545 Phase 3 study) UPA 15 mg QD monotherapy (UPA Mono) demonstrated significant and clinically meaningful improvements in RA signs and…Abstract Number: 1425 • ACR Convergence 2021
Voclosporin for Lupus Nephritis: Interim Analysis of the AURORA 2 Extension Study
Background/Purpose: Voclosporin, a novel calcineurin inhibitor (CNI), has been tested successfully in 2 pivotal trials in adult patients with lupus nephritis (LN). Previously reported results…Abstract Number: 1700 • ACR Convergence 2021
Pharmacokinetic Boosting to Enable Once-Daily Reduced Dose Tofacitinib
Background/Purpose: Tofacitinib is an effective, yet costly, drug for treatment of RA and PsA. Tofacitinib is metabolized mainly by the cytochrome P450-enzyme CYP3A4, and the…Abstract Number: 1765 • ACR Convergence 2021
Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG A and/or Two BILAG B Domain Scores?
Background/Purpose: High placebo response rates have challenged interpretation of clinical trial results in SLE and may have contributed to failure of some effective treatments. One…Abstract Number: 1856 • ACR Convergence 2021
Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous SSc
Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) carries a highly variable prognosis and to date there are no stratification tools to predict clinical outcomes. Evidence suggests…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 44
- Next Page »